Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients

ClinicalTrials.gov ID: NCT02290873

Public ClinicalTrials.gov record NCT02290873. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Double-blind, Randomized, Placebo and Active Controlled, Multi-center, Parallel Group Study Comparing Remimazolam to Placebo, With an Additional Open-label Arm For Midazolam, in Patients Undergoing a Colonoscopy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A prospective, double-blind, randomized, placebo and active controlled, multi-center, parallel group study comparing remimazolam to placebo, with an additional open-label arm for midazolam, in patients undergoing a colonoscopy for diagnostic or therapeutic reasons.

Study identification

NCT ID
NCT02290873
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Paion UK Ltd.
Industry
Enrollment
461 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 29, 2015
Primary completion
Mar 31, 2016
Completion
Apr 18, 2016
Last update posted
Oct 19, 2020

2015 – 2016

United States locations

U.S. sites
13
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
University of South Alabama Mobile Alabama 36688
Advanced Clinical Research Institute Anaheim California 92801
Precision Research Institute Chula Vista California 91910
Precision Research Institute San Diego California 92114
Borland-Grover Clinic, P.A Jacksonville Florida 32256
Indiana University Health Indianapolis Indiana 46202
Delta Research Partners Inc Monroe Louisiana 71201
Washington University School of Medicine St Louis Missouri 63110
Wake Research Associates Raleigh North Carolina 27612
Cleveland Clinic Foundation Cleveland Ohio 44195
Thomas Jefferson Medical College Philadelphia Pennsylvania 19107
Nashville Medical Research Institute Nashville Tennessee 37205
Gastroenterology Associates of Tidewater Chesapeake Virginia 23320

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02290873, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 19, 2020 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02290873 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →